Figure 2.
Genetic deletion and pharmacological inhibition of PAI-1 improves glucose tolerance and insulin sensitivity. (A,B) Glucose tolerance tests (GTT) and AUC in each group. N = 6 per group. *P < 0.05 vs. ND-WT; **P < 0.05 vs. ND-WT; #P < 0.05 vs. HFD-WT vehicle. HFD was associated with elevated fasting glucose levels and impaired glucose tolerance. PA1-1 depletion or inhibition (C,D) Insulin tolerance tests (ITT) and AUC in each group. N = 6 per group. *P < 0.05 vs. ND-WT; **P < 0.05 vs. ND-WT; #P < 0.05 vs. HFD-WT.
